
    
      Patients who meet the eligibility criteria (patients admitted to hospital with confirmed
      COVID-19 infection associated to D-dimer > 3 times the ULN) will be invited to participate in
      the proposed study and, following the application of the informed consent form, will be
      randomized to 2 groups in the 1:1 ratio. Group 1 will follow the strategy of routine use of
      full anticoagulation therapy (oral or parenteral); and group 2 will follow the usual standard
      care without full anticoagulation.
    
  